XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Moderna Collaboration and License Agreement - Narratives (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
target
Jul. 03, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
product
target
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
target
obligation
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Moderna Collaboration and License Agreement                    
Collaboration revenues         $ 3,400 $ 3,800 $ 16,000 $ 10,600    
Deferred revenue liability $ 41,932       41,932 46,185 41,932 46,185 $ 46,413 $ 47,459
Collaboration revenues         3,385 $ 3,827 15,979 $ 10,630    
Option Right Collaboration Revenues                    
Moderna Collaboration and License Agreement                    
Collaboration revenues             3,800      
Milestones                    
Moderna Collaboration and License Agreement                    
Collaboration revenues             $ 2,000      
Collaboration and License Agreement                    
Moderna Collaboration and License Agreement                    
Number of potential research target designations | target             12      
Collaboration and License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Variable consideration             $ 73,900      
Term of contract (in years)             5 years      
Noncurrent portion of deferred revenue $ 41,300       41,300   $ 41,300      
Moderna License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Collaboration revenues             35,000      
Moderna License Agreement | Option Right Collaboration Revenues                    
Moderna Collaboration and License Agreement                    
Collaboration revenues             3,800      
Moderna | Collaboration and License Agreement                    
Moderna Collaboration and License Agreement                    
Maximum of research targets | target       12            
Number of research targets, designate as development targets | target 12                  
Number of nominated autoimmune target | target       2            
Number of research targets designated | target 7                  
Moderna | Collaboration and License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Upfront non-refundable payment received       $ 45,000     $ 45,000      
Number of potential products to develop and commercialize | product       12            
Minimum commitment to reimburse research and development costs       $ 10,000            
Period of reimbursement of research and development costs (in years)       3 years            
Number of performance obligations | obligation             2      
Moderna | Collaboration and License Agreement | Research and Development Services | Minimum                    
Moderna Collaboration and License Agreement                    
Amount receivable per product       $ 247,000            
Moderna | Collaboration and License Agreement | Research and Development Services | Maximum                    
Moderna Collaboration and License Agreement                    
Amount receivable per product       $ 253,000            
Moderna | Moderna License Agreement                    
Moderna Collaboration and License Agreement                    
Milestone payment     $ 2,000              
Collaboration revenues     $ 2,000              
Proceeds related to collaboration revenue   $ 2,000                
Deferred revenue liability $ 45,000       $ 45,000   $ 45,000      
Decrease in contract with customer, liability             $ 3,800